AKT1 and hepatocellular carcinoma: Our findings support the initiation of clinical trials in HCC patients, suggesting that, for the high-risk HCC subgroup characterized by activated PI3K/Akt signaling, combining PI3K/Akt inhibitors with ICIs may offer a more effective therapeutic strategy.